Cosmos Health Enters Agreement To Acquire Remaining 40% Rights To WIPO-Filed CNS Cancer Drug Patent, Strengthening Global Brain Tumor Market Position; Financial Terms Of Transaction Not Disclosed

Author: Benzinga Newsdesk | June 18, 2024 10:03am

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an agreement to acquire all remaining rights arising from the patent filed with the World Intellectual Property Organization (WIPO) under reference code PCT/EP2023/071865. This follows the agreement announced on December 7, 2023, where Cosmos Health had acquired 60% of the rights.

Posted In: COSM